
Motsoaledi's big HIV treatment jump: Is it true?
Last month, the health minister said that more than half a million previously diagnosed people with HIV have been started on treatment since the end of February.
But can it really be, especially since the gap to getting 95% of people diagnosed with HIV on medication has been hovering around 1-million for the past five years?
Critics say they're sceptical about the minister's figures — and that the country will close the gap by December.
Numbers are powerful.
They can also be dangerous — if not used correctly.
When the health minister said last month that 520 700 extra people previously diagnosed with HIV had been started on treatment since the end of February, the number sounded astounding.
The health department's goal is to find 1.1-million people who know they have HIV, but either never started treatment, or fell out of treatment, before the end of the year.
In his words, the department has reached 'more than 50% of the target' they set out to achieve by the end of the year.
If that gap is closed, South Africa would have met two of the three so-called 95-95-95 goals the country signed up for as part of the United Nations plan to end Aids as a public health threat by 2030.
However, knowing by exactly how much the gap is closing is tricky, because people who know they have HIV may start and stop and then restart treatment again later — sometimes several times — during the course of their care.
In fact, a study from the Western Cape shows that close to half of people on medication stop at least once, and that some even pause and then restart up to three times.
So, many of the 520 700 previously diagnosed people Motsoaledi says are now on medication could, at least in theory, very well be people who are counted repeatedly as they cycle in and out of treatment. But because the patient information system isn't digitally centralised — most clinics still keep track of their clients on paper, which means different facilities can't easily access one another's records — someone who stops treatment at one clinic can easily be counted as a new start at another, rather than a restart.
The set of UN targets aim for 95% of people in a country with HIV to know their diagnosis, 95% of those to be on treatment and 95% of those taking medication to have such low levels of virus in their bodies that they can't infect someone through sex.
'The reason that we [were] able to reach half a million within a short space of time, was because of weekly check-in meetings with provinces, where reports that come from the ground are verified in the presence of all provincial colleagues before they are regarded as final figures for reporting,' said the minister.
But simply counting better isn't the same as doing better, and critics called the reported progress 'inconceivable'.
Why?
Because for the last few years, the number of people with HIV who have gone on treatment has crept up very slowly, so much so that the gap to 95% has remained more or less the same for about five years. (At the moment just over 80% of people diagnosed with HIV are on treatment.)*
Moreover, that was while treatment programmes had funding and US-backed money for HIV projects was in place.
So now, at a time of funding shortfalls, programmes closing and the government scrambling to plug the holes, could nearly half of the number of people who need to get on treatment really have been added in just 10 weeks?
We dive into the data to get a sense of what the numbers really mean.
Mind the gap
In 2021, South Africa was about 1.2 million people short of its 95%-treatment goal; by 2025 the shortfall will likely be 990 000. That means that the gap — that is, the difference between where the country actually is and where it wants to be when it comes to HIV treatment — has closed by about 210 000.
Bhekisisa
So, there's been progress, but it's been slow: in total, only about 700 000 more people are on HIV medication today than five years ago.
'Getting that last one million or so people on treatment is not simple,' says Kate Rees, public health specialist at the Anova Health Institute. Part of the reason for this, she says, is that a large proportion of the group needed to close the gap are people who have in fact been on ARVs before but have since stopped.
Sometimes people miss an appointment to get a refill of their medicine because they can't afford to take time off work to go to the clinic or they might have moved to another province or district and so they don't go back to the facility where they first got their prescription, she explains. The longer the interruption lasts, the more hesitant people are to go back, says Rees, because they dread being treated poorly or getting 'kicked to the back of the queue' for having missed an appointment, with especially people like sex workers, trans folk or men who have sex with men facing judgement.
Says Rees: 'The health service expects people to be very rigid with their appointments, but life just is not like that.'
Slow progress
To get a sense of the progress towards meeting the UN's second target in its 95-95-95 cascade, it's best to look at the difference in the total number of people on HIV treatment from year to year, says Leigh Johnson, one of the lead developers of the Thembisa model, which is used to report South Africa's official statistics to UNAids.
Bhekisisa
Although the number of people on medication is increasing, the number grows less and less each year. For example, in 2020, about 291 000 more people were on treatment than in 2019. By 2021, though, the number had grown only by about 225 000.
Current forecasts from the model are that the total number of people on treatment will grow by only around 160 000 this year. But that's based on programmes running like they have up to now — and with recent upsets because of US funding cuts, it may be an unreasonable assumption, Johnson says.
Part of the reason for the small net gain every year, is that although many people sign up for medication in a year, many also stop coming back to get their scripts refilled. Of those who drop out of treatment, some might choose to restart within a couple of months again, while others may pause their treatment for more than a year.
Bhekisisa
In 2023, for example, roughly 793 500 people who had been on treatment before weren't any longer, but about 728 000 who received medication were restarters, Thembisa numbers show.
Bhekisisa
So even though some people who stop taking their medication might not restart — or restart quickly — the total number who are on treatment still grows; it's just slow-going. This means getting a handle on how close to — or far from — the 95%-treatment mark South Africa is, is more dynamic than simple addition.
Stops, starts and restarts
'There will always be people who interrupt their treatment,' says Rees. 'It's not possible to keep everyone perfectly in the system all the time — that's life.'
But what's important, she says, is to make those pauses as short as possible by helping people to get back on medication quickly and easily — without judgement.
Gesine Meyer-Rath agrees. She's a health economist at HE2RO, a health economics research group at the University of the Witwatersrand, and focuses on how the government can get the most bang for its buck in its HIV programme.
Data in the Thembisa model shows that over the years, the number of people starting medication for the first time — in other words, those who have never been on treatment before — has shrunk, but at the same time counts of restarters have grown. Her group's analyses have shown that honing in on keeping people on HIV treatment is the best way to go — especially now that funding is shrinking — and that 'we can close the 1.1-million gap through improved retention alone'.
But to plan sensibly, she explains, policymakers should know how many people are first-time starters, how many pause treatment but then restart, and how many stop and don't come back at all.
'The more detail programme planners have in the data, the better,' she says. 'The [government's] 'Close the Gap' campaign has a lot of good ideas, but having the right numbers of where the gap is that we want to close is crucial, as is keeping these numbers accurate as we progress.'
This is exactly where things can become tricky in future if the holes left by the US funding cuts aren't plugged.
Because of the US's aid withdrawal, about 40% of South Africa's HIV data capturers will likely have lost their jobs by September, Bhekisisa reported last month, and this means the information needed to shape where money has to be spent to make real progress in ending Aids as a public health threat over the next five years simply might not be available.
Says Meyer-Rath: 'The less data we have, the more we're flying blind, which leaves space for bickering over the data that is still there.'
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Addus HomeCare (ADUS) Q2 Earnings: What To Expect
Home healthcare provider Addus HomeCare (NASDAQ:ADUS) will be reporting results this Monday afternoon. Here's what you need to know. Addus HomeCare missed analysts' revenue expectations by 0.6% last quarter, reporting revenues of $337.7 million, up 20.3% year on year. It was a mixed quarter for the company, with a narrow beat of analysts' sales volume estimates. Is Addus HomeCare a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Addus HomeCare's revenue to grow 20.8% year on year to $346.5 million, improving from the 10.4% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $1.46 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Addus HomeCare has missed Wall Street's revenue estimates three times over the last two years. Looking at Addus HomeCare's peers in the senior health, home health & hospice segment, some have already reported their Q2 results, giving us a hint as to what we can expect. BrightSpring Health Services delivered year-on-year revenue growth of 15.3%, beating analysts' expectations by 5.2%, and Option Care Health reported revenues up 15.4%, topping estimates by 4.6%. Option Care Health traded down 2.7% following the results. Read our full analysis of BrightSpring Health Services's results here and Option Care Health's results here. The euphoria surrounding Trump's November win lit a fire under major indices, but potential tariffs have caused the market to do a 180 in 2025. While some of the senior health, home health & hospice stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 4.3% on average over the last month. Addus HomeCare is down 5.3% during the same time and is heading into earnings with an average analyst price target of $136.45 (compared to the current share price of $104.74). Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Encompass Health (EHC) Reports Q2: Everything You Need To Know Ahead Of Earnings
Health care services provider Encompass Health (NYSE:EHC) will be announcing earnings results this Monday afternoon. Here's what you need to know. Encompass Health beat analysts' revenue expectations by 1.7% last quarter, reporting revenues of $1.46 billion, up 10.6% year on year. It was a strong quarter for the company, with an impressive beat of analysts' full-year EPS guidance estimates and a solid beat of analysts' EPS estimates. Is Encompass Health a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Encompass Health's revenue to grow 9.6% year on year to $1.43 billion, in line with the 9.6% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $1.21 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Encompass Health has only missed Wall Street's revenue estimates once over the last two years, exceeding top-line expectations by 1.5% on average. Looking at Encompass Health's peers in the healthcare providers & services segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Select Medical delivered year-on-year revenue growth of 4.5%, meeting analysts' expectations, and CVS Health reported revenues up 8.4%, topping estimates by 5.1%. Select Medical traded down 15.1% following the results while CVS Health's stock price was unchanged. Read our full analysis of Select Medical's results here and CVS Health's results here. Questions about potential tariffs and corporate tax changes have caused much volatility in 2025. While some of the healthcare providers & services stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 4.3% on average over the last month. Encompass Health is down 9.1% during the same time and is heading into earnings with an average analyst price target of $131.58 (compared to the current share price of $108.53). When a company has more cash than it knows what to do with, buying back its own shares can make a lot of sense–as long as the price is right. Luckily, we've found one, a low-priced stock that is gushing free cash flow AND buying back shares. Click here to claim your Special Free Report on a fallen angel growth story that is already recovering from a setback. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
Yahoo
an hour ago
- Yahoo
"I Was Billed Over $2m For A Week In The Hospital": 51 Horrifying Photos That Encapsulate American Healthcare
in America is genuinely dystopian. should not have to advertise for a kidney. this make sense. me again how America is the greatest country in the world? work should 100% be a part of routine or preventative care. should also be able to talk about your child's medical issues at their physical??? absolutely ridiculous to require a subscription on TOP of health insurance you already pay for. Related: people a heart transplant because they can't pay for the meds shouldn't be a thing, because the meds should be covered in the first place. is so, so bleak. is this. healthcare is so expensive and stressful that it's actually making people's mental health WORSE. a horrific cycle... just goes on and on. me to remind you that the inventors of insulin sold the patents for $1 so that everyone who needed it could afford it. 16."But private healthcare means you can choose your doctors!" policy doesn't even make sense unless you view it through a lens of greed. should NOT be a business. Related: can't possibly cost this much for the hospital to treat a rattlesnake bite. the point of an annual physical if not to check in on any issues? medical care should cost $620k. person didn't even receive any medical care and got charged almost $1.5k. someone explain why it costs $316 just to get evaluated over the phone? me how this is "cosmetic" when the person is in pain. HOURS??? are we even paying for? Related: I'm 99% positive "Nancy" is an incompetent AI bot. 28.I will never understand why ambulance rides are so expensive. This was for a few MINUTES-long ride. are literally having to refuse ambulances — that they NEED — because they're so expensive. is ridiculous. should not be legal. with this. companies are dickheads. They want to make it impossible to get a cent from them. 35.I'm asking the same question. is one of the many reasons why we should have universal healthcare that isn't tied to your job. are really out here looking for coupons for medical care, that's how bad it is. is the bad place. is such BS. If you can't read the above, it says: American Insurance (55M) Had a heart attack, died, revived and my cardiologist wouldn't let me leave the hospital without a LifeVest (portable defibulator). It automatically triggers in case of another cardiac incident. I spent two extra days in the hospital because insurance didn't want to approve the LifeVest. That cost the insurance another $20,000ish. They finally relented and let me have a LifeVest. Now, they say they don't have to pay for the LifeVest. Everyone, the American insurance system (read scam) in a single sentence!!! "Your plan doesn't provide coverage for services that are considered investigational or not medically necessary. The fact that a provider may prescribe, order, recommend or approve a service, treatment, medication, or supply does not make it Medically Necessary or a Covered Service, and does not guarantee payment. These terms are defined in the 'Definition' section of your health plan document." Related: is this. If you can't read the above, it says: Diagnosis: I26.99 Oth Pulmonary Embolism W/O Acute Cor PulmonaleDate(s) determined not to be medically necessary: 11/29/2024 - 11/30/2024 The clinical reason for our determination is:You were admitted to the hospital on 11/29/2024. The reason is blood clot to lung. We read the medical records given to us. We read the guidelines for a hospital stay. This stay does not meet the guidelines. You did not have to be admitted as an inpatient in the hospital for this care. The reason is you were watched closely in the hospital. You were stable. You had tests that did not show any problems that needed inpatient only treatment. The records showed your blood pressure was not too low. You did not need a breathing machine. You could have gotten the care you needed without being admitted inpatient at the hospital. The hospital inpatient admission is not covered. We let the hospital know that it is not covered. insurance isn't going to approve life-saving medicine, what's even the point of having insurance? was this $528??? (After insurance, too!) should not cost $15/capsule. one should have to go without life-saving care because they don't want to have to live for a medical bill. is just completely unhinged. should not be this expensive. good insurance can be great, but tell me why it's almost $40k to begin with??? healthcare is a scam. is so predatory. are you supposed to afford these rates at $9/hour? Never mind the deductibles and copays? finally, this is just genuinely bonkers. The entire system needs to change. Also in In the News: Also in In the News: Also in In the News: